Prostate cancer is the second most common cancer and sixth leading cause of cancer death among men worldwide, with an estimated recorded number of 1.1 million cases and 307,000 deaths which allocates 15% of all new cases of cancer in men. Androgen receptor (AR) expression is maintained throughout prostate cancer progression, and the majority of androgen –independent or hormone refractory prostate cancers express Androgen receptor. HER2/neu, a biological marker named human epidermal growth factor receptor -2[EGFR-2] is also known as c-erb-2 plays a major role in understanding the oncogenesis of prostate adenocarcinoma and has a significant prognosis in the disease. Aim of The Study: To study the histomorphological features and grading of prostatic neoplasms with Gleason’s scoring. To study over the expression of HER2/neu & androgen receptor status in prostate neoplasm. To study the correlation of Gleason’s scoring with AR & HER2/neu expression in prostate cancer. All patients who were diagnosed to have prostatic cancer and PIN and were diagnosed by prostatic biopsy either by prostatectomy, TURP or Trucut procedure were included in the study and were examined for analyzing various histomorphological features and grading of various neoplasms of prostate with correlation to overexpression of immmunohistochemical markers Her2/neu and AR. Conclusion: This study may help the clinician in finding out her2/neu over expressed cases and implementing anti her2/neu therapy along with androgen deprived therapy for longer survival of prostate cancer patients although further studies on larger series of prostate carcinoma is required for new generation of more efficient anti her2 drugs.